الفهرس 
Gene polymorphisms associated with nonalcoholic fatty liver disease
ABSTRACTOnly 14 pages are availabe for public view
 |  | from | 210 |  |  |
| | | from | 210 | | |
Abstract
NAFLD is one of the fast-growing health problems that affects up to 25% of people around the world. The gold standard for obtaining relevant information on the progression of NAFLD is the liver biopsy. However, numerous studies clearly imply that liver biopsy should no longer be considered necessary as a first-line technique of evaluation in certain chronic liver illnesses due to the limitations and hazards of biopsy, as well as improvements in the diagnostic accuracy of new noninvasive markers. Genetic factors are increasingly being recognized as important in the pathophysiology of NAFLD. The PNPLA3 gene is expressed in both adipocytes and hepatocytes and is recognized to be a critical regulator of lipid metabolism in the liver. The factors involved in the control of PNPLA3 expression are incompletely understood. However, mutations in the non-coding regulatory regions of PNPLA3 have been described. Additionally, the association between SNP (E167K) in TM6SF2 and the risk for non-alcoholic fatty liver disease occurrence was studied.
Gene expression of CD24 was detected by qRT-PCR to evaluate its diagnostic accuracy as a non-invasive tool for diagnosis of NAFLD at an early stage. We tried to develop a noninvasive diagnostic tool for the early detection of patients who have a risk to develop NAFLD.